Corporate Tech Investors

Shenzhen Hepalink Pharmaceutical

Shenzhen Hepalink Pharmaceutical is a corporate venture capital group that makes equity investment in startup ventures that can advance its organizational interests.

Venture Investor Overview

Contact Information

Background Information

Overview

Shenzhen Hepalink Pharmaceutical Co., Ltd (Hepalink) distributes its product, Heparin Sodium API in the global market to internationally renowned pharmaceutical companies, such as Sanofi-Aventis, Fresenius -Kabi, and Novartis. Hepalink was established in 1998 and restructured in 2007 to be a limited liability company. Hepalink went public and was listed on the Shenzhen Stock Exchange on May 6, 2010 (stock code 002399). Hepalink's headquarters are located in the Shenzhen High-Tech Park.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

7/18/2017

Transaction History

Our records indicate that Shenzhen Hepalink Pharmaceutical invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

President

Li Li

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

Shenzhen Hepalink Pharmaceutical has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Browse more corporate investors:

Shell Technology Ventures | Shenzhen Salubris Pharmaceuticals

Share this article

About Our Corporate Tech Investor Database

This corporate tech investment data comes via a partnership with VentureDeal.com, a leading supplier of corporate VC funding data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary